Low-dose aspirin should be used in colorectal cancer prevention studies, researchers say.
This article was originally published in The Tan Sheet
Executive Summary
LOW-DOSE ASPIRIN FOR COLORECTAL CANCER STUDIES SUGGESTED based on the results of a 66-patient, 14-day study measuring the effect of aspirin at 40.5 mg, 81 mg, 162 mg, 324 mg and 648 mg daily on prostaglandins E2 and F2alpha. The short-term study by Mack Ruffin et al., University of Michigan, published in the Aug. 6 Journal of the National Cancer Institute, was conducted to determine the lowest dose of aspirin that could significantly reduce the level of colorectal prostaglandins as a baseline for future studies seeking to find new chemopreventive agents for colorectal cancers. High levels of prostaglandins have been found in colon cancer tissues.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning